Hepatitis Clinical Trials

Find Hepatitis Clinical Trials Near You

Recompensation in Alcohol Related Hepatitis- A Prospective Cohort With Alcohol Cessation

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Genetic activity and metabolic changes may be part of the pathogenesis in alcohol related hepatitis. We do not know exactly how alcohol cessation affects liver functions and metabolism. The aim of this study is to assess the impact of alcohol cessation in patients with alcohol related hepatitis and gain knowledge of the metabolic and genetic functions of the liver during remission and recompensation from alcohol related hepatitis. The study will assess 1. The effect of alcohol cessation on the liver. 2. The biological mechanisms involved in healing after alvohol-cessation 3. The effect of motivational enhcament therapy in alcohol cessation after alcohol related hepatitis. 4. The metabolic changes of lipids and proteins in the liver Participants are offered motivational enhancement therapy and standard of care.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Clinical suspicion of AH, supported by biochemistry (bilirubin 50 mmol/l or higher) and ultrasound or other imaging techniques.

• Informed written consent.

Locations
Other Locations
Denmark
University Hospital Hvidovre
RECRUITING
Hvidovre
Contact Information
Primary
Nina Kimer, MD, PhD
nina.kimer@regionh.dk
+4525140961
Backup
Niels P Klausen, MD
niels.peter.riedel.klausen@regionh.dk
+4538621968
Time Frame
Start Date: 2024-11-25
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 160
Treatments
Experimental: Treatment
Standard of Care: medical treatment of alcohol use disorder and motivational enhacement therapy, three interviews within three months.
Related Therapeutic Areas
Sponsors
Collaborators: The Novo Nordisk Foundation Center for Basic Metabolic Research, Copenhagen University Hospital, Hvidovre
Leads: Nina Kimer

This content was sourced from clinicaltrials.gov